Any decrease inthe availability of iron for incorporation into the heme moieties of hemoglobin results in an increase in the erythrocyte protoporphyrin concentration. Our aim was to compare protoporphyrin concentrations, determined spectrophotometrically, with body iron stores, as assessed from the amount of iron demonstrable by Prussian blue staining of bone marrow aspirates. The mean protoporphyrin concentration (175 zg/dl) in the erythrocytes of a group of patients with markedly decreased stainable marrow iron or no iron was significantly greater (P <.00 1) than the mean concentration (76 tg/dl) in a comparable group with adequate bone marrow iron stores, except in the presence of certain interfering conditions. These results suggest that the erythrocyte protoporphyrin test may be a useful addition to the methods now available for assessing disorders of heme synthesis, the most common of which is irondeficiency.
Additional Keyphrases: bone marrow iron #{149} diagnostic aids #{149} lead exposure #{149} method evaluation #{149} nutritional biochemistry #{149} population surveys Routine methods used for detecting iron deficiency [hemoglobin and hematocrit determinations, erythrocyte indices (1) , and erythrocyte morphology on peripheral blood smears (1, 2) ] lack specificity and reliably indicate only iron deficiency that has progressed to the point of anemia. Other, more reliable methods include 57Co excretion (3), 59Fe absorption (4), percent saturation of transferrin, and Prussian blue staining of marrow aspirates.
The concentration of protoporphyrin in erythrocytes has previously been shown to be increased in persons with iron deficiency (5) (6) (7) (8) (9) (10) (11) (12) , but until recently its determination has been too involved for routine clinical use. Increased interest in using protoporphyrin measurements diagnostically has stimulated the development of simplified assays for protoporphyrin (13) (14) (15) (16) (17) (18) , which have greatly facilitated study of this problem.
Dagg et al. (10) demonstrated that protoporphyrin is increased in the sideropenic state, which they defined as "hemoglobin levels between 12 and 13 g per dl, a saturation of the total iron-binding capacity less than 16 percent, and an absence of stainable iron in the bone marrow."
We have compared protoporphyrin concentrations of persons whose iron stores are adequate with those of persons whose iron stores are markedly decreased or depleted. We have also compared such values with the amount of diffuse marrow iron as assessed histochemically by a system that distinguishes diffuse iron-said to be the form of storage iron that is available for erythropoiesis-from so-called polymorphous iron (19). Hematocrit, erythrocyte morphology, and measurements of serum iron were also recorded. In addition, we measured protoporphyrin concentrations in patients with infection, neoplastic disease, or liver disease. Our purpose was to see if protoporphyrin measurements are a valid index of iron deficiency.
Procedures

Subjects and Specimen Collection
All hospitalized patients from whom a bone marrow aspirate was obtained at Grady Memorial Hospital, Atlanta, Ga., during the period of this study were considered.
We attempted to obtain blood for protoporphyrin analysis from each of them. Whole blood (5 ml) was collected in a Vacutainer tube (Becton-Dickinson, Rutherford, N. J. 07070) containing ethylenediaminetetraacetic acid as the anticoagulant. Exposure of the blood to light was minimized, and the sample was frozen (within 2-3 h of collection). Protoporphyrin analysis was done within 2 to 10 days. Bone marrow aspirates were stained by the Prussian blue reaction and counterstained with hematoxyhin and eosin to localize the cells. Other standard stains were made at the same time on other aliquots of the marrow for routine bone marrow examination.
A person with no knowledge of the patient's condition did the protoporphyrin analyses; a physician with no knowledge of the analytical result obtained relevant clinical information from the hospital charts.
Measurement of Erythrocyte Protoporphyrin Concentration3
This was measured, with minor modifications, according to the spectrophotometric method of Heller et al. (13) , whole blood samples being used. After the porphyrins were extracted, the result was calculated according to the following equation (13, 20, 21 portion of porphyrins other than protoporphyrin in the erythrocytes of normal subjects is seldom greater than 5% of the total porphyrins (24), the result can be called "erythrocyte protoporphyrin" for all practical purposes. Further, although whole blood rather than washed erythrocytes is used for assay, the fact that almost all the blood porphyrin is intracellular (24) means that little inaccuracy is introduced.
Data we obtained with pooled whole blood, stored at -20 #{176}C, indicated a coefficient of variation (CV) of 15%. This CV includes both the within-day and dayto-day variation.
If we were to calculate only the within-day components, as has been suggested (12, 25) , the CV would be only 5%, but this gives a false impression of the true precision. Quality control was maintained by running two to four control vialsfrom the whole blood pool each day with the patients'samples. We could not detect a decrease in the protoporphyrin concentration of the pooled specimen during 120 days; thereafter, the value decreased to about 80% of the original.
Subsequently, no further decrease was measured through 193 days. A second pooled specimen, collected five months after the first, showed no decrease in protoporphyrin during 118 days.
Examination of Bone Marrow Aspirate for Stainable Iron
Bone marrow aspirates, prepared as described above, were examined for stainable iron. In all cases, a preliminary qualitative examination was made, and the marrows were described as "iron present," "iron absent," or "iron present but decreased."
A subsample of the total group was re-examined and graded according to the criteria proposed by Hausmann and Kuse (19). Thus, each marrow in this subset was given a grade with respect to the "diffuse" iron and separately with respect to the "polymorphous" iron. The former was defined as either fine granules of iron in reticuloendothelial cells or the presence of normal sideroblasts with usually only one or a few granule(s) of iron stain in the cytoplasm. The latter was defined as coarse granules of iron in reticuloendothelial cells. Two independent observers examined a number of fields in scattered areas of each marrow and graded them with respect to diffuse or polymorphous iron in the marrow, according to the following scale: 0, Absence of iron The statistical analysis was the same as that described for diffuse marrow iron, except that x was the observed percent saturation. Caraway procedure (26); these were run on blood drawn between 0700 and 0900 hours while the patients were fasting.
Results
We studied 95 patients on whom a bone marrow aspirate or biopsy, or both, had been performed. Of these, 73 (77%) were suitable for evaluation; the remaining 22 were excluded, either because no diagnosis was made (i.e., fever of unknown origin) or because two or more conditions (other than iron deficiency) that are known to cause an increase in protoporphyrin were present, including infection, liver disease, malignancy, hemolysis, and lead poisoning. Among the 73 patients evaluated in detail, 15 patients had adequate iron stores and no condition known to cause an increase in protoporphyrin, 14 had iron deficiency (defined as absence or near absence of stainable marrow iron), and 44 others, both with and without iron deficiency, had one other condition known to affect protoporphyrin concentration: infection (18 patients), liver disease (12 patients),or malignant disease (14 patients).
In addition to these 73 patients, a separate group of nine patients with hemolysis is listed, bringing the overall total to 82 (86%). These were not evaluated along with the others because all but one of them had at least one other condition, besides hemolysis, known to increase protoporphyrin concentrations; the one exception had a left flank mass of unknown etiology. Table 1 lists the results for each of these groups. Figure 1 shows the protoporphyrin results for patients with and without adequate marrow iron and with no other condition known to elevate protoporphyrin (the first 29 cases from Table 1 ). The mean protoporphyri.n concentration in the 15 patients with adequate marrow iron stores was 76 tg/dl of erythrocytes (SD, 24 /Lg/dl). These 15 patients constitute the control group. In the 14 patients with iron deficiency, the mean protoporphyrin concentration was 175 1Lg/dl of erythrocytes (SD 62 g/dl); the difference between the two groups is highly significant (P <.001). When marrow iron stores were classified according to the amount of diffuse marrow iron present, there was a moderately strong inverse relationship between the protoporphyrin concentration and diffuse iron; i.e., higher protoporphyrin concentrations correlated with decreasing amounts of diffuse marrow iron. The mathematical relationship, derived BONE MARROW IRON Fig. 1 . Protoporphyrin (PROTO) concentrations in patients having adequate bone marrow iron stores compared with those whose iron stores are markedly depleted or absent Horizontal line represents the calculated upper limit of normal for protoporphyrin from the observed data with a least-square technique, is represented by the line in Figure 2 ; the correlation. 
Analysis
of this data suggests that the best single estimate of the upper limit of normal for protoporphyrin is 94 og/dl of erythrocytes for patients with adequate marrow iron (based on the assumption that adequate marrow iron corresponds to a grade of (+)/+ or greater, which in turn corresponds to the "adequate" group in Figure 1 ). The 95% confidence limits for this figure are 80 to 110 ig/dl of erythrocytes.
If the mean protoporphyrin concentration in the group with iron of (+)/+ or greater is compared that of the group with (+) or less, the difference is highly significant (P <.005). Using the same type of statistical analysis as for diffuse marrow iron stores, we found that the relationship between protoporphyrin and polymorphous marrow iron was not as strong (r = -.67). An inverse relationship was also found between protoporphyrin and percent saturation of transferrin in the patients represented in Figure 1 (r = -.63), but the relationship was not as strong as that between protoporphyrin and diffuse marrow iron. Protoporphyrin correlated with serum iron (inversely) and with T.I.B.C.
(r = -.50 and +.51, respectively), but these relationships (r = .23).6 All the iron-deficient patients with hypochromia, however, had increased protoporphyrin concentrations, and there was a definite correlation between the two (r = .65). 6 Protoporphyrin apparently was not related to iron stores in the other groups of patients. Among the infected patients, there were 45% false positives (abnormally increased protoporphyrin) in patients with adequate marrow iron, and one false negative (normal protoporphyrin) in the patients assessed as having markedly decreased or absent marrow iron. Both false positives and false negatives were found in the Numbers 1 to 5 were assigned to the symbols tr, 1+, 2+, 3+, and 4+, respectively.
The analysis was the same as for marrow iron grade and percent saturation. figure: degree of microcytosis; second figure: hypochromla). t Marrow Iron grade is given for those patients whose bone marrow iron stains could be retrieved for review; first figure given is for diffuse iron, second is for polymorphous iron (see Methods). Marrow iron stores as originally estimated by first examiner as either adequate or absent (or markedly decreased). Patients with megaloblastic anemia. It Patients with azotemia.
**
Patients who had received blood transfusion prior to obtaining sample for PROTO; these were not Included in statistical analysis of PROTO vs. marrow iron, but are included here for completeness.
patients with liver disease (60% false positive, one false negative) and those with malignant disease (27% false positive, one false negative). When marrow iron stains in infected patients were graded according to the amount of diffuse iron present (see Table 1 ), there was still no relationship between marrow iron and protoporphyrin.
Ten patients of the total of 95 (all patients in Table 1 , plus 13 others not shown) had megaloblastic anemia; all protoporphyrin increases (four of the 10) in these patients could be explained on the basis of iron deficiency or other conditions known to affect protoporphyrin.
This also applies to six patients with elevated protoporphyrin among 13 patients with azotemia (blood urea nitrogen >300 mg/liter); all six had at least one condition known to increase protoporphyrin.
In patients with hemolysis (nine of 95 patients), one abnormally high protoporphyrin value (287 1ig/dl of erythrocytes) occurred in a patient for whom no explanation for this could be found other than the hemolysis itself (which was due to congenital ovalocytosis).
Two patients than most values reported in the literature (6, 9, 10, 24, (29) (30) (31) , but seemed to be consistent with the upper limit of about 100 ag/dl of erythrocytes proposed by the originators of the method we used (13) .
Protoporphyrin has often been shown to be increased in patients with infection (12), malignancy (7), liver disease (30), and lead poisoning (15) , and the same was found in this study. Elevated erythrocyte protoporphyrin has also been found in patients with thalassemia (30). Increased extracorporeal (in vitro) synthesis of protoporphyrin has been observed in cases of sickle cell anemia and of thalassemia major with reticulocytosis (32). In the case of infection and malignancy, the protoporphyrin increase may be related to the fact that re-utilization of iron is blocked (33, 34), whereas in liver disease the explanation is not clear. We cannot confirm whether a block in re-utilization of iron explains the lack of correlation between protoporphyrin and marrow iron in malignancy and infection; the lack of a relationship between protoporphyrin and diffuse marrow iron in infection suggests that such a block is not discernible by routine examination of the marrow for morphology of iron stores. Protoporphyrin is increased in some patients with hemolysis (12) ; this may depend on whether the rate of hemolysis is great enough to result in a demand for iron in excess of the iron transport system's ability to deliver it to rubricytes. This could explain the one patient with hemolysis in our series who had an increased protoporphyrin but adequate iron stores and for whom there was no other explanation for such an increase. There was no relationship between protoporphyrin and azotemia, which is consistent with the experience of others (12) .
This series consisted entirely of hospitalized patients, many of whom were severely ill with multisystern diseases. Use of this population brought out the fact that protoporphyrin measurements, although a sensitive indicator of iron deficiency, lack specificity; this may limit the applicability of the test in such patients. The high sensitivity of protoporphyrin to the iron-deficient state, however, may nevertheless offer some advantage when it is used as a screening test or survey tool for detection of iron deficiency.
In situations where liver disease or an inflammatory condition is a complicating factor, thus making interpretation of an elevated protoporphyrin difficult, measurement of serum ferritin may be of value (35). The latter has been shown to be depressed in iron deficiency, but not in liver disease or inflammation (35). In addition, the protoporphyrin concentration is more stable than serum iron, which undergoes diurnal variation and fluctuations in response to infection, or recent dietary intake. New fluorometric methods (14) (15) (16) (17) make it possible to measure protoporphyrin in blood from a finger prick, which at present cannot readily be done in the case of serum iron and T.I.B.C.
These newer methods promise to be simpler and faster than the one we used in this study. Determination of protoporphyrin by such methods may prove to be practical in screening for disordered heme synthesis caused by iron deficiency or lead poisoning. We7 and others (14, 16) 
